Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States
- Written by Reporters
HONG KONG SAR - Media OutReach - 22 February 2021 - This announcement is made by Ocumension Therapeutics (the "Company", together with its subsidiaries, the "Group") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.
The board of directors...